Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: SonoVue
SonoVue is an ultrasound contrast agent consisting of sulfur hexafluoride microbubbles. It is administered intravenously to enhance the visibility of blood vessels and organs during ultrasound examinations. The microbubbles resonate and scatter ultrasound waves, creating a stronger signal that improves image quality. This allows for more detailed visualization of blood flow and tissue perfusion, aiding in the diagnosis of various medical conditions.
Used to enhance ultrasound imaging of the heart, liver, and other organs and vessels.
Outcome:
Increased risk of arrhythmias
Mechanism:
Additive effects on heart rate and contractility
Outcome:
Reduced efficacy of dobutamine stress echocardiography
Mechanism:
Pharmacodynamic interaction
Outcome:
May interfere with image quality
Mechanism:
Unknown
Most likely new formulation: Targeted microbubbles for specific disease detection (Year: 2026, 75% confidence)
Based on current usage trends and clinical trial data, there is a 90% likelihood of SonoVue maintaining its approved status for ultrasound contrast enhancement in the next 5 years.
Ultrasound Contrast Agent
Sulfur Hexafluoride